• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

32例骨巨细胞瘤中RANKL、OPG和RUNX2的表达及表观遗传修饰

RANKL, OPG, and RUNX2 expression and epigenetic modifications in giant cell tumour of bone in 32 patients.

作者信息

Amri Raja, Chelly Ameni, Ayedi Mariem, Rebaii Mohamed Ali, Aifa Sami, Masmoudi Sabeur, Keskes Hassib

机构信息

Research Laboratory Cell Therapy and Experimental Musculoskeletal System, Faculty of Medicine, Sfax, Tunisia.

Laboratory of Molecular and Cellular Screening Processes, Centre of Biotechnology of Sfax, Sfax, Tunisia.

出版信息

Bone Joint Res. 2024 Feb 19;13(2):83-90. doi: 10.1302/2046-3758.132.BJR-2023-0023.R2.

DOI:10.1302/2046-3758.132.BJR-2023-0023.R2
PMID:38368904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10875390/
Abstract

AIMS

The present study investigated receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), and Runt-related transcription factor 2 (RUNX2) gene expressions in giant cell tumour of bone (GCTB) patients in relationship with tumour recurrence. We also aimed to investigate the influence of CpG methylation on the transcriptional levels of RANKL and OPG.

METHODS

A total of 32 GCTB tissue samples were analyzed, and the expression of RANKL, OPG, and RUNX2 was evaluated by quantitative polymerase chain reaction (qPCR). The methylation status of RANKL and OPG was also evaluated by quantitative methylation-specific polymerase chain reaction (qMSP).

RESULTS

We found that RANKL and RUNX2 gene expression was upregulated more in recurrent than in non-recurrent GCTB tissues, while OPG gene expression was downregulated more in recurrent than in non-recurrent GCTB tissues. Additionally, we proved that changes in DNA methylation contribute to upregulating the expression of RANKL and downregulating the expression of OPG, which are critical for bone homeostasis and GCTB development.

CONCLUSION

Our results suggest that the overexpression of RANKL/RUNX2 and the lower expression of OPG are associated with recurrence in GCTB patients.

摘要

目的

本研究调查骨巨细胞瘤（GCTB）患者中核因子κB受体激活剂配体（RANKL）、骨保护素（OPG）和 runt 相关转录因子 2（RUNX2）基因表达与肿瘤复发的关系。我们还旨在研究 CpG 甲基化对 RANKL 和 OPG 转录水平的影响。

方法

共分析 32 例 GCTB 组织样本，通过定量聚合酶链反应（qPCR）评估 RANKL、OPG 和 RUNX2 的表达。还通过定量甲基化特异性聚合酶链反应（qMSP）评估 RANKL 和 OPG 的甲基化状态。

结果

我们发现，与非复发性 GCTB 组织相比，复发性 GCTB 组织中 RANKL 和 RUNX2 基因表达上调更明显，而复发性 GCTB 组织中 OPG 基因表达下调更明显。此外，我们证明 DNA 甲基化的变化有助于上调 RANKL 的表达并下调 OPG 的表达，这对骨稳态和 GCTB 的发展至关重要。

结论

我们的结果表明，RANKL/RUNX2 的过表达和 OPG 的低表达与 GCTB 患者的复发有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/89754cfc1bf1/BJR-2023-0023.R2-galleyfig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/082bd34348d9/BJR-2023-0023.R2-galleyfig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/2407e6bbc0d2/BJR-2023-0023.R2-galleyfig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/f7c3e7442191/BJR-2023-0023.R2-galleyfig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/89754cfc1bf1/BJR-2023-0023.R2-galleyfig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/082bd34348d9/BJR-2023-0023.R2-galleyfig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/2407e6bbc0d2/BJR-2023-0023.R2-galleyfig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/f7c3e7442191/BJR-2023-0023.R2-galleyfig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b217/10875390/89754cfc1bf1/BJR-2023-0023.R2-galleyfig4.jpg

相似文献

1
RANKL, OPG, and RUNX2 expression and epigenetic modifications in giant cell tumour of bone in 32 patients.32例骨巨细胞瘤中RANKL、OPG和RUNX2的表达及表观遗传修饰
Bone Joint Res. 2024 Feb 19;13(2):83-90. doi: 10.1302/2046-3758.132.BJR-2023-0023.R2.
2
Role of DNA methylation in the regulation of the RANKL-OPG system in human bone.DNA 甲基化在人骨中 RANKL-OPG 系统调控中的作用。
Epigenetics. 2012 Jan 1;7(1):83-91. doi: 10.4161/epi.7.1.18753.
3
Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis.DNA 甲基化对原发性骨质疏松症中 OPG/RANKL 表达的影响。
Int J Med Sci. 2018 Oct 3;15(13):1480-1485. doi: 10.7150/ijms.27333. eCollection 2018.
4
Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.Runx2通过核因子κB受体激活剂配体（RANKL）诱导破骨细胞分化及对骨保护素的调节，并通过RANKL转基因部分挽救Runx2基因敲除小鼠的破骨细胞生成。
J Biol Chem. 2003 Jun 27;278(26):23971-7. doi: 10.1074/jbc.M302457200. Epub 2003 Apr 15.
5
Mechanical strain-mediated reduction in RANKL expression is associated with RUNX2 and BRD2.机械应变介导的RANKL表达降低与RUNX2和BRD2相关。
Gene X. 2020 Jan 16;5:100027. doi: 10.1016/j.gene.2020.100027. eCollection 2020 Dec.
6
The Role of MicroRNA-143-5p in the Differentiation of Dental Pulp Stem Cells into Odontoblasts by Targeting Runx2 via the OPG/RANKL Signaling Pathway.microRNA-143-5p 通过靶向 OPG/RANKL 信号通路调控 Runx2 对牙髓干细胞向成牙本质细胞分化的作用
J Cell Biochem. 2018 Jan;119(1):536-546. doi: 10.1002/jcb.26212. Epub 2017 Jul 24.
7
Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.乳腺癌中核因子-κB 受体激活剂（RANK）、RANK 配体（RANKL）和骨保护素（OPG）的表达谱。
Anticancer Res. 2013 Jan;33(1):199-206.
8
BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl/Opg expression ratio in osteoblasts.骨形态发生蛋白诱导的Atoh8通过抑制Runx2转录活性并降低成骨细胞中Rankl/Opg表达比率来减弱破骨细胞生成。
Bone Res. 2020 Sep 2;8(1):32. doi: 10.1038/s41413-020-00106-0. eCollection 2020.
9
Is vitamin D deficiency behind the scenes for high incidence of Giant cell tumor amongst the Indian population? Unraveling the vitamin D - RANKL association.维生素 D 缺乏是否是印度人群中巨细胞瘤高发的幕后黑手？揭示维生素 D - RANKL 关联。
Med Hypotheses. 2019 Feb;123:67-71. doi: 10.1016/j.mehy.2018.12.010. Epub 2018 Dec 21.
10
RNA interference-mediated osteoprotegerin silencing increases the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio and promotes osteoclastogenesis.RNA干扰介导的骨保护素沉默增加了核因子-κB受体激活因子配体/骨保护素比值并促进破骨细胞生成。
World J Stem Cells. 2025 Apr 26;17(4):101290. doi: 10.4252/wjsc.v17.i4.101290.

本文引用的文献

1
A systematic review of multicentric giant cell tumour with the presentation of three cases at long-term follow-up.多中心性巨细胞瘤的系统评价及三例长期随访病例报告
Bone Joint J. 2022 Dec;104-B(12):1352-1361. doi: 10.1302/0301-620X.104B12.BJJ-2022-0401.R1.
2
[Giant-cell tumor of bone in 2022].[2022年骨巨细胞瘤]
Ann Pathol. 2022 Apr;42(3):214-226. doi: 10.1016/j.annpat.2022.03.004. Epub 2022 May 3.
3
A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences.
骨靶向治疗与酪氨酸激酶抑制剂联合应用于骨巨细胞瘤和促纤维组织增生性纤维瘤的作用原理：转化医学证据
Biomedicines. 2022 Feb 3;10(2):372. doi: 10.3390/biomedicines10020372.
4
Giant Cell Tumor of Bone: An Update.骨巨细胞瘤：最新进展。
Curr Oncol Rep. 2021 Mar 22;23(5):51. doi: 10.1007/s11912-021-01047-5.
5
DNA methylation across the genome in aged human skeletal muscle tissue and muscle-derived cells: the role of HOX genes and physical activity.人类骨骼肌组织和肌源性细胞中全基因组的 DNA 甲基化：HOX 基因和体力活动的作用。
Sci Rep. 2020 Sep 21;10(1):15360. doi: 10.1038/s41598-020-72730-z.
6
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.PD-L1 和免疫相关基因表达谱在骨巨细胞瘤中的预后作用。
Cancer Immunol Immunother. 2020 Sep;69(9):1905-1916. doi: 10.1007/s00262-020-02594-9. Epub 2020 May 6.
7
Functions of Exogenous RUNX2 in Giant Cell Tumor of Bone In Vitro.外源性 RUNX2 在骨巨细胞瘤中的作用的体外研究。
Orthop Surg. 2020 Apr;12(2):668-678. doi: 10.1111/os.12568. Epub 2020 Mar 10.
8
Molecular Mechanism of Runx2-Dependent Bone Development.Runx2 依赖性骨发育的分子机制。
Mol Cells. 2020 Feb 29;43(2):168-175. doi: 10.14348/molcells.2019.0244.
9
Epigenome-wide association study of DNA methylation and microRNA expression highlights novel pathways for human complex traits.全基因组范围内的 DNA 甲基化和 microRNA 表达的表观基因组关联研究突出了人类复杂特征的新途径。
Epigenetics. 2020 Jan-Feb;15(1-2):183-198. doi: 10.1080/15592294.2019.1640547. Epub 2019 Jul 17.
10
Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience.地舒单抗是否改变了骨巨细胞瘤的治疗策略？早期经验教训。
Clin Orthop Relat Res. 2018 Sep;476(9):1773-1782. doi: 10.1007/s11999.0000000000000243.